Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years, after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, ...

Rahway, N.J.-based Merck (MRK) had net income of $3.743 billion, or $1.48 a share, for the quarter, after a loss of $1.226 ...

Included are Type-2 diabetes drugs Janumet, Janumet XR, Ozempic, Rybelsus, Tradjenta and Wegovy. The federal Centers for Medicare and Medicaid Services disclosed the 15 drugs that would be covered ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation ...

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug ...

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle ...

Medicare will continue to negotiate drug prices in 2025. (HealthDay News) — Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...

The new prices are expected to take effect in 2027. HealthDay News — Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities ...